US2015110816A1PendingUtilityA1
Methods of treatment using anti-erbb antibody-maytansinoid conjugates
Est. expiryMar 16, 2020(expired)· nominal 20-yr term from priority
A01K 67/0278A01K 2267/0331A01K 67/0275A61K 47/6871A61P 35/00A01K 2227/105C07K 16/2863A01K 2217/05A01K 2207/15C12N 15/8509A61K 47/6855A61K 2039/505A61K 39/39558A01K 2217/052A61K 9/0019C07K 2317/24C07K 16/32A01K 2217/00A61K 31/5365A61K 47/48384C07K 16/3015A61K 47/68033A01K 67/0271
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
Claims
exact text as granted — not AI-modified1 - 36 . (canceled)
37 . A method of treating a breast cancer characterized by overexpression of ErbB2 in a mammal comprising administering to the mammal a therapeutically effective amount of huMAb4D5-8 conjugated to DM1 via a disulfide or thioether group.
38 . The method of claim 37 , wherein huMab4D5-8 and DM1 are conjugated via a disulfide group.
39 . The method of claim 38 , wherein the disulfide group is N-succinimidyl-4-(2-pyridylthio)pentanoate.
40 . The method of claim 38 , wherein the disulfide group is N-succinimidyl-3-(2-pyridyldithio)propionate.
41 . The method of claim 37 , wherein huMab4D5-8 and DM1 are conjugated via a thioether group.
42 . The method of claim 41 , wherein the thioether group is succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate.
43 . The method of claim 37 , wherein the mammal is a human.
44 . The method of claim 39 , wherein the mammal is a human.
45 . The method of claim 40 , wherein the mammal is a human.
46 . The method of claim 42 , wherein the mammal is a human.
47 . The method of claim 37 , wherein the breast cancer does not respond or responds poorly to treatment with huMAb4D5-8.
48 . The method of claim 44 , wherein the breast cancer does not respond or responds poorly to treatment with huMAb4D5-8.
49 . The method of claim 45 , wherein the breast cancer does not respond or responds poorly to treatment with huMAb4D5-8.
50 . The method of claim 46 , wherein the breast cancer does not respond or responds poorly to treatment with huMAb4D5-8.
51 . The method of claim 37 , wherein the breast cancer overexpresses ErbB2 at a 2+ level or more.
52 . The method of claim 44 , wherein the breast cancer overexpresses ErbB2 at a 2+ level or more.
53 . The method of claim 45 , wherein the breast cancer overexpresses ErbB2 at a 2+ level or more.
54 . The method of claim 46 , wherein the breast cancer overexpresses ErbB2 at a 2+ level or more.
55 . The method of claim 37 , wherein the breast cancer overexpresses ErbB2 at a 3+ level or more.
56 . The method of claim 44 , wherein the breast cancer overexpresses ErbB2 at a 3+ level or more.
57 . The method of claim 45 , wherein the breast cancer overexpresses ErbB2 at a 3+ level or more.
58 . The method of claim 46 , wherein the breast cancer overexpresses ErbB2 at a 3+ level or more.
59 . The method of claim 37 , wherein administration is intravenous.
60 . The method of claim 37 , wherein the conjugate comprises from 3 to 5 maytansinoid molecules per huMAb4D5-8 molecule.
61 . The method of claim 37 , wherein the method further comprises treatment with a second anti-ErbB2 antibody.
62 . The method of claim 61 , wherein the second anti-ErbB2 antibody is 2C4 or a humanized variant thereof.Join the waitlist — get patent alerts
Track US2015110816A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.